Healthcare Innovation Group Warns MFN Drug Pricing Plan Would Harm Illinois Patients and Jobs (Chicago, IL) – A leading Illinois health innovation group is sounding the alarm over a federal drug pricing proposal it says would stifle medical research, cost jobs, and limit patient access to new treatments.
In a statement released this week, Joshua Justin Travis, executive director of the Center for Healthcare Innovation, criticized the “Most Favored Nation” (MFN) model under debate in Washington, D.C. The plan would tie the price of U.S. prescription drugs to those in foreign countries with government-controlled healthcare systems.
While pitched as a way to lower costs for patients, Travis argued the approach is “a blunt instrument aimed at the wrong target” that threatens Illinois’ $101 billion biopharmaceutical sector. That industry supports nearly 45,000 direct jobs, more than 263,000 total jobs, and funds around 2,700 clinical trials involving 1.9 million Illinois residents.
“MFN punishes the very companies that invest in Illinois’ economy and develop the lifesaving therapies our communities depend on,” Travis said. “Instead of reforming pharmacy benefit managers and other middlemen who drive up prices, it would undermine innovation, weaken our economy, and ultimately hurt patients.”
The group warned that linking U.S. prices to foreign benchmarks would discourage domestic research and accelerate the shift of drug development overseas, particularly to China, which has already surpassed the U.S. in the number of clinical trials. Countries with similar price controls, Travis noted, approve only about half the innovative medicines available in the U.S.
Supporters of MFN say the model could lower prescription drug costs for American patients, but critics like the Center for Healthcare Innovation argue that any savings would come at the expense of future treatments and high-paying jobs.
Instead, the group urged Congress to focus on reforms that increase transparency in the practices of pharmacy benefit managers, ensuring that savings flow directly to patients without weakening Illinois’ research economy.
“The choice is clear,” Travis said. “Stand with Illinois’ workers, researchers, and patients. Stand against MFN.”
Healthcare Innovation Group Warns MFN Drug Pricing Plan Would Harm Illinois Patients and Jobs
